Jerome Thurman is an Endocrinology/Metabolic physician. OpenAlex indexes 9 publications with 376 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
711 Veterans Memorial Pkwy Ste 200
Saint Charles, MO 633032106
Telephone
636-669-2219Provider last certified this registry record 27 Oct 2020.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year202535 payments$18,997openpaymentsdata.cms.gov ↗
- Sequel Med Tech, LLCProgram year202529 payments
- Medtronic, Inc.Program year202511 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
60.2%Insulin Analog19.4%Toujeo Max Solostar27%Tresiba Flextouch U-20011%Tresiba Flextouch U-1009%Humalog Kwikpen U-1009%Lantus Solostar9%Toujeo Solostar6%Novolog Flexpen6%Insulin Lispro Kwikpen U-1005%Humalog3%Soliqua 100-333%Fiasp Flextouch3%Novolog2%Xultophy 100-3.61%Fiasp1%Basaglar Kwikpen U-1001%Lyumjev Kwikpen U-1001%Lantus1%Humalog Kwikpen U-2001%Insulin Lispro1%Part D<11 patientsGLP-1 receptor agonist12.8%Ozempic75%Trulicity12%Mounjaro7%Rybelsus4%Victoza 3-Pak2%Part D<11 patients+ 9 more classes in this area
Hormonal (systemic)
19.6%l-Thyroxine15%Levothyroxine Sodium74%Synthroid22%Unithroid2%Levoxyl1%Part D<11 patientsThyroid Hormone Synthesis Inhibitor3%Methimazole100%Part D≥64 patients+ 5 more classes in this area
Cardiovascular
9.5%Statin4.1%Atorvastatin Calcium36%Rosuvastatin Calcium34%Pravastatin Sodium16%Simvastatin14%Part D≥32 patientsAngiotensin receptor blocker (ARB)1.7%Losartan Potassium90%Olmesartan Medoxomil10%Part D<11 patients+ 7 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Healthcare professional and patient perceptions of a new prefilled insulin pen versus vial and syringe
Expert Opinion on Drug Delivery
2012 - Usability and preference evaluation of a prefilled insulin pen with a novel injection mechanism by people with diabetes and healthcare professionals
Current Medical Research and Opinion
2011 - Analysis of Insulin Pen Devices for the Treatment of Diabetes Mellitus
Journal of Diabetes Science and Technology
2008
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”